Salvage therapy with pegylated liposomial doxorubicin-based regimen in relapsed/refractory multiple myeloma: comments to the article by Romano et al

Romano A. et al. have recently published an interesting study on the efficacy of a salvage regimen with pegylated liposomial doxorubicin, cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma patients (rrMM). As the authors clearly demonstrated, this regimen can be really effective and safe also for rrMM patients previously treated with novel agents (median of previous lines: 2, r. 1-6), with clinical response in 12 patients (50%), 29% of which being VGPR or better, with 8.7 months PFS and 21.5 months OS (r. 2-44 months), after a median follow-up of 21.5 months (1). This article is protected by copyright. All rights reserved.